Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
1.315
-0.035 (-2.59%)
Mar 31, 2025, 10:56 AM EDT - Market open

Quince Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2017
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2017
Selling, General & Admin
15.0815.424.9129.5217.59
Upgrade
Research & Development
18.599.2525.1860.861.31
Upgrade
Operating Expenses
33.6724.6450.0990.3278.89
Upgrade
Operating Income
-33.67-24.64-50.09-90.32-78.89
Upgrade
Interest & Investment Income
2.933.481.070.622.04
Upgrade
Currency Exchange Gain (Loss)
-0.680-0.77-0.25-
Upgrade
Other Non Operating Income (Expenses)
-1.71-0.34---
Upgrade
EBT Excluding Unusual Items
-33.13-21.5-49.79-89.95-76.85
Upgrade
Merger & Restructuring Charges
-2.5-2.5-1.1--
Upgrade
Impairment of Goodwill
-17.13--0.83--
Upgrade
Gain (Loss) on Sale of Assets
--0.04-0.09--
Upgrade
Asset Writedown
--5.97-0.14--
Upgrade
Other Unusual Items
-3.99-1.58---
Upgrade
Pretax Income
-56.74-31.58-51.94-89.95-76.85
Upgrade
Income Tax Expense
0.09-0.2-0.28--
Upgrade
Net Income
-56.83-31.39-51.66-89.95-76.85
Upgrade
Net Income to Common
-56.83-31.39-51.66-89.95-76.85
Upgrade
Shares Outstanding (Basic)
4337333029
Upgrade
Shares Outstanding (Diluted)
4337333029
Upgrade
Shares Change (YoY)
16.18%11.17%12.71%1.86%53.30%
Upgrade
EPS (Basic)
-1.31-0.84-1.54-3.03-2.63
Upgrade
EPS (Diluted)
-1.31-0.84-1.54-3.03-2.63
Upgrade
Free Cash Flow
-32.16-18.45-44.17-63.11-50.87
Upgrade
Free Cash Flow Per Share
-0.74-0.50-1.32-2.12-1.74
Upgrade
EBITDA
-33.48-24.32-49.89-89.97-78.56
Upgrade
D&A For EBITDA
0.190.320.20.340.33
Upgrade
EBIT
-33.67-24.64-50.09-90.32-78.89
Upgrade
Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q